AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
19.20
-0.74 (-3.71%)
Nov 5, 2024, 11:14 AM EST - Market open
AnaptysBio Employees
AnaptysBio had 117 employees as of December 31, 2023. The number of employees increased by 21 or 21.88% compared to the previous year.
Employees
117
Change (1Y)
21
Growth (1Y)
21.88%
Revenue / Employee
$260,453
Profits / Employee
-$1,453,974
Market Cap
579.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Fulgent Genetics | 1,184 |
OrthoPediatrics | 247 |
ORIC Pharmaceuticals | 100 |
Y-mAbs Therapeutics | 100 |
ABIVAX Société Anonyme | 61 |
Astria Therapeutics | 59 |
Mereo BioPharma Group | 33 |
Opthea | 33 |
ANAB News
- 2 months ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire
- 2 months ago - AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point - Seeking Alpha
- 2 months ago - Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering - GlobeNewsWire
- 3 months ago - Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst - Benzinga
- 6 months ago - Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) - GlobeNewsWire
- 6 months ago - Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties - GlobeNewsWire